Outcome of Board Meeting held on Wednesday, May 28, 2025
VIKASLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vikas Lifecare's board approved its audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, along with a clean (unmodified) audit opinion from statutory auditors KSMC & Associates. Full-year revenue from operations grew ~11% YoY to ₹46,357.62 lakhs (vs ₹41,672.23 lakhs), but the company slipped into a net loss of ₹225.66 lakhs versus a profit of ₹1,932.43 lakhs in FY24, while Q4 FY25 posted a small net profit of ₹91.38 lakhs. Other income spiked sharply to ₹2,097.70 lakhs in Q4 (from ₹494.28 lakhs YoY), and depreciation, finance costs, and other expenses rose materially. The board also elevated COO Kamal Ghildiyal to Director (Commercial) and appointed internal, cost, and secretarial auditors for FY25-26. Notes flag two major risk items: a ₹18.25 crore GST demand (under appeal) and ongoing arbitration over a USD 34.827 million contribution to the Eraaya-led Ebix acquisition, while operating cash flow turned sharply negative at ₹(23,285) lakhs.
The revenue growth is encouraging, but the swing to a full-year loss, deeply negative operating cash flow, GST demand, and unresolved Ebix-related arbitration are significant overhangs that may weigh on the stock. Shareholders should watch the GST appeal outcome, arbitration progress, and whether profitability and cash generation recover in FY26.